VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT WITH CIPLA USA, INC. FOR IRINOTECAN LIPOSOME INJECTION

Hong Kong Exchanges and Clearing Limited and The Stock Excha nge of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoe ver for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this ann ouncement. CSPC PHARMACEUTICAL GROUP LIMITED (Incorporated in Hong Kong with limited liability) (Stock Code: 1093) ʮ ̡ VOLUNTARY ANNOUNCEMENT EXCLUSIVE LICENSE AGREEMENT WITH CIPLA USA, INC. FOR IRINOTECAN LIPOSOME INJECTION The board of directors (the ‘‘Board ’’) of CSPC Pharmaceutical Group Limited (the ‘‘Company ’’, together with its subsidiaries, the ‘‘Group ’’) is pleased to announce that the Group has entered into an exclusive license agreement (the ‘‘Agreement ’’) with Cipla USA, Inc. ( ‘‘Cipla ’’) for the commercialization of the Group ’s Irinotecan Liposome Injection (the ‘‘Product ’’) in the United States (the ‘‘Territory ’’). Under the terms of the Agreement, the Group agreed to grant an exclusive license to Cipla to commercialize the Product in the Territory. The Group will r eceive an upfront payment of US$15 million, and is also eligible to receive potential first com mercial sale and regulatory milestone payments of up to US$25 million and potential additional com mercial sales milestone payments of up to US$1,025 million, plus tiered double-digit royalties ba sed on annual net sales of the Product in the Territory. ABOUT THE PRODUCT The Product is one of the representative innovative drugs in dependently developed under the liposome technology platform of the Group. The Product, a topoisomer ase 1 inhibitor, is supplied as a sterile, white to slightly yellow opaque isotonic liposomal dispers ion containing 43mg/10ml irinotecan. Irinotecan is currently used for the treatment of multiple s olid tumors such as metastatic pancreatic cancer, colorectal cancer, lung cancer and cervical cancer . It is a component in many combination regimens such as FOLFIRI or FOLFIRINOX for the treatment of t hese types of cancers. ABOUT CIPLA Cipla USA, Inc. is a pharmaceutical company headquartered i n the United States which is committed to providing patients access to high-quality drugs. By order of the Board CSPC Pharmaceutical Group Limited CAI Dongchen Chairman Hong Kong, 15 May 2025 – 1 – As at the date of this announcement, the Board comprises Mr. C AI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chu nlei, Dr. YAO Bing, Mr. CAI Xin and Mr. CHEN Weiping as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Steph en and Ms. LI Quan as independent non-executive directors. – 2 –

The release as fetched from its publisher. irasia.com ↗